Methotrexate

Showing study: Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease (Feagan et al.)

Benefits

Risk

Overtime:
SHOW:
grid-1
grid-1

Benefit

Harm

Study overview

  • Figure shows absolute benefit/risk. This is calculated by assessing benefit/risk of study drug against placebo, except where stated
  • Double-blind, placebo-controlled, multicenter study of patients with chronically active Crohn's disease who had entered remission after 16 to 24 weeks of treatment with 25 mg of methotrexate given intramuscularly once weekly
  • Patients were randomly assigned to receive either methotrexate at a dose of 15 mg intramuscularly once weekly or placebo for 40 weeks
  • Remission was defined as a score of 150 or less on the Crohn's Disease Activity Index

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.